跳至主要内容
临床试验/NCT03649672
NCT03649672终止不适用

The Validity and Tolerability of Awake Calibration of the TOF Watch SX® Monitor: An Interventional Prospective Single Two-center Study

Christoph Czarnetzki4 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2018年10月26日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
64
试验地点
4
主要终点
Total recovery time

研究概览

简要总结

Neuromuscular blocking agents (NMBAs) are frequently used in anesthesia and quantitative monitoring of neuromuscular block is standard care. Normally the calibration of the neuromuscular monitor is done after anesthesia induction to avoid patient discomfort. Under certain circumstances there is no time for the calibration process. In the so-called rapid sequence induction (RSI) the neuromuscular blocking agent has to be injected immediately after the induction agent. As the neuromuscular monitor cannot be calibrated, precise neuromuscular monitoring is not possible, and this is of particular disadvantage, when high doses of non-depolarizing neuromuscular blockers are injected to fasten the onset of neuromuscular block. The primary objective is to validate the measurements of the TOF Watch SX® monitor calibrated in awake patients by comparing them with the measurements obtained with the TOF Watch SX® monitor calibrated after anesthesia induction (Gold standard).

The secondary objective is to evaluate the tolerability of the awake calibration process of the TOF Watch SX® monitor.

详细描述

Neuromuscular function will be assessed by acceleromyography of the adductor pollicis with a TOF-Watch SX® monitor on both arms. By randomization it will be chosen on which arm the awake calibration will be done. 5 minutes before the awake calibration process the patients will receive 0.2 µg/kg of sufentanil intravenously. Immediately after the end of the calibration process the patients will rate the pain of the calibration process on a visual analog scale from 0 to 10. Anesthesia will then be induced and immediately at loss of consciousness continuous TOF stimulation will be continued every 12s. Then the calibration process on the other arm will be started, followed by continuous TOF stimulation. After having obtained stable baseline measurements with the TOF-Watch SX® monitor, a bolus dose of rocuronium 0.6 mg kg-1 will be administered intravenously. The trachea will be intubated when full neuromuscular block is reached. No additional rocuronium will be given. Both neuromuscular monitors will be linked via a fiber-optic (TOF-Link®) cable with UBS port to a laptop. Specific software will be used to record the measurements (TOF watch SX® monitor, version 2.2). Neuromuscular monitoring will be continued until a normalized TOF ratio of 0.9 has been obtained on both arms. The onset of neuromuscular block and its spontaneous recovery will be recorded and the results obtained on each arm will be compared. Every patient is his own control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • American Society of Anesthesiologists class I or II
  • patients undergoing elective surgery lasting at least 60 minutes under general anesthesia requiring neuromuscular blockade using rocuronium bromide for endotracheal intubation

排除标准

  • Patient with a history of allergy or hypersensitivity to rocuronium.
  • Patients with neuromuscular disease
  • Patients with preoperative medications known to influence neuromuscular function (for instance aminoglycosides, phenytoin, lidocaine)
  • Patients with electrolyte abnormalities (for instance, hypermagnesemia)
  • Patients with a body mass index <19 or >30 kg m2
  • Patient having participated in any clinical trial within 30 days, inclusive, of signing the informed consent form of the current trial
  • Patients undergoing interventions that need a continuous deep neuromuscular block
  • Pregnant or breast feeding women

结局指标

主要结局

Total recovery time

时间窗: during the duration of the general anesthesia

Total duration of the neuromuscular block defined as the time in minutes from start of injection of rocuronium until a normalized TOF ratio of 90%

次要结局

  • Dur TOFc1(during the duration of the general anesthesia)
  • Dur TOF 75%(during the duration of the general anesthesia)
  • Dur TOF 25%(during the duration of the general anesthesia)
  • TOF pain: VAS(before inductin of general anesthesia)
  • Dur TOF 50%(during the duration of the general anesthesia)
  • Onset time(during the duration of the general anesthesia)

研究者

发起方
Christoph Czarnetzki
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Christoph Czarnetzki

MD, MBA

University Hospital, Geneva

研究点 (4)

Loading locations...

相似试验

The Validity and Tolerability of Awake Calibration... | 临床试验